Candida auris (C. auris)
C. auris is an emerging, often multi-drug resistant fungus that can cause serious infections and presents a global health threat. C. auris was first reported in the United States in 2016 (and is a nationally notifiable disease/pathogen).
Why is C. auris considered an emerging threat?
It was first identified in 2009. Since that time, it has been increasing in frequency and has now been reported in multiple countries and across the United States.
It may cause serious infections and can lead to serious outcomes. High mortality rates are associated with invasive C. auris infections, particularly bloodstream infections.
It is often resistant to multiple antifungal drugs commonly used to treat candida infections. Some strains are resistant to all three available classes of antifungals.
Frequently Asked Questions
External Links
Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales
Enterobacterales are a group of bacteria that cause infections in healthcare settings and communities.
- Some species are also a normal part of the human gut.
- Some Enterobacterales produce enzymes called extended-spectrum beta-lactamases (ESBLs).
- Extended-spectrum beta-lactamases (ESBLs) break down certain antibiotics, making some infections caused by ESBL-producing Enterobacterales difficult to treat.
Additional Materials
ESBL FAQs Coming Soon
Key points
- Good hand hygiene and infection prevention practices can help reduce infection risk.
- Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales are resistant to common antibiotics and may require complex treatments.
- Infections caused by ESBL-producing Enterobacterales can occur both in and outside of healthcare settings.
